Cancer
Breast cancer in Hangzhou
杭州 乳腺癌
9 hospitals in Hangzhou
Order: papers led on breast cancer, 2021–2025, then A–Z. Research activity, not a rating of care.
Only hospitals listed for breast cancer: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Hangzhou may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.
- 110 papers led
- Second Affiliated Hospital, Zhejiang University浙江大学医学院附属第二医院International Medical Department visitor guide109 papers led
- 74 papers led
- 64 papers led
- 49 papers ledNo open trial led
- 49 papers led
- 21 papers ledNo open trial led
- 6 papers ledNo open trial led
- 0 papers led
Breast cancer in every city Hangzhou on the disease page, with the national map
open trials on breast cancer with a hospital in Hangzhou
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Hangzhou as lead sponsor or study site. 61 of them are led by a hospital in Hangzhou. Check the registry for the current status. Whether someone can take part is decided by the study team.
Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.
- Recruitingthe Efficacy of Leucogen in Preventing the Risk of Ribociclib-Associated Neutropenia in Early Breast Cancer
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07380646
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingNeoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)
- Phase
- Phase 2
- Started
- 2026-02
- Posted
- Registry
- NCT07383818
Age 18 years to 70 years; women only (registered criteria)
Led by First Affiliated Hospital, Zhejiang University; 4 listed hospitals as study sitesHangzhou, Harbin, Hefei, Shanghai, Xi'an
- RecruitingRO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
- Phase
- Phase 2/Phase 3
- Started
- 2026-05
- Posted
- Registry
- NCT07413939
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanjing, Nanning, Shanghai, Shantou, Tianjin, Urumqi, Wuhan
- RecruitingNeoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07457359
Age 18 years to 75 years; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingBGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
- Phase
- Phase 3
- Started
- 2026-05
- Posted
- Registry
- NCT07492641
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Kunming, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Shijiazhuang, Tianjin, Weifang, Wenzhou, Wuhan, Xi'an, Zhengzhou
- RecruitingEfficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07498478
Age 18 years to Not stated; women only (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Changsha, Chongqing, Guangzhou, Hangzhou, Jinan, Linyi, Nanjing, Shanghai, Tianjin, Wuhan
- RecruitingMetronomic Oral Paclitaxel Monotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose-Finding and Expansion Study
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07602907
Age 18 years to Not stated (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingFovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer
- Phase
- Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07616427
Age 18 years to 75 years; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang University; 1 listed hospital as study siteHangzhou, Nanjing
- RecruitingPilot Study on the Clinical Efficacy of Focused Ultrasound-Mediated Targeted Drug Delivery System Combined With Neoadjuvant Therapy for HER2-Positive Breast Cancer
- Phase
- N/A
- Started
- 2026-06
- Posted
- Registry
- NCT07616440
Age 18 years to 70 years; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingEfficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07616453
Age 18 years to 75 years; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingOlaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast Cancer
- Phase
- Phase 4
- Started
- 2026-05
- Posted
- Registry
- NCT07695259
Age 60 years to Not stated; women only (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingSMP-656 for HER2-Positive Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07726342
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing, Shenyang, Shijiazhuang, Wuhan, Xi'an, Zhengzhou
- RecruitingEffects of TDCS Intervention on Neoadjuvant Chemotherapy in Breast Cancer Patients with Mild to Moderate Depression
- Phase
- N/A
- Started
- 2025-01
- Posted
- Registry
- NCT06741540
Age 18 years to 65 years; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingBGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
- Phase
- Phase 1
- Started
- 2025-02
- Posted
- Registry
- NCT06756932
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesGuangzhou, Hangzhou, Shanghai, Tianjin, Zhengzhou
- RecruitingPhase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT06757634
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changsha, Hangzhou, Jinan, Luoyang, Nanchang, Nanjing, Ningbo, Shenyang, Tianjin, Weifang, Xi'an, Xinxiang, Yangzhou, Zhengzhou
- RecruitingTo Investigate the Real-world Efficacy and Safety of Sacituzumab Govitecan for HER2 Negative Metastatic Breast Cancer Patients in China.
- Phase
- Not given
- Started
- 2025-02
- Posted
- Registry
- NCT06784921
Age 18 years to 75 years; women only (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingA Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Phase
- Phase 3
- Started
- 2025-04
- Posted
- Registry
- NCT06790693
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Kunming, Nanning, Tianjin, Urumqi, Xi'an, Xiangyang
- RecruitingA Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Phase
- Phase 3
- Started
- 2025-03
- Posted
- Registry
- NCT06841354
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanjing, Nanning, Taiyuan, Taizhou, Urumqi, Wuhan, Xi'an, Xiamen, Xiangyang, Xuzhou, Zhengzhou
- RecruitingNeoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)
- Phase
- Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT06874933
Age 18 years to 75 years; women only (registered criteria)
Led by First Affiliated Hospital, Zhejiang University; 2 listed hospitals as study sitesHangzhou
- RecruitingA Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT06891833
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 26 listed hospitals as study sitesAnyang, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Luoyang, Nanchang, Nanning, Shanghai, Shenzhen, Shijiazhuang, Taiyuan, Tianjin, Xi'an, Zhengzhou
- RecruitingA Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Phase
- Phase 2/Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT06926868
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesAnyang, Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanning, Qingdao, Shenyang, Taiyuan, Tianjin, Wuhan, Xiangyang, Zhengzhou
- RecruitingNeoadjuvant High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab and Chemotherapy for ER-Positive /HER2-Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2025-03
- Posted
- Registry
- NCT06964906
Age 18 years to 75 years; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT06966700
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Changchun, Changsha, Hangzhou, Harbin, Hefei, Jinan, Nanjing, Nanning, Shanghai, Urumqi, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingNeoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)
- Phase
- Phase 3
- Started
- 2025-03
- Posted
- Registry
- NCT06977893
Age 18 years to 75 years; women only (registered criteria)
Led by First Affiliated Hospital, Zhejiang University; 9 listed hospitals as study sitesHangzhou, Harbin, Hefei, Nanchang, Shanghai, Urumqi, Xi'an, Zhengzhou
- RecruitingJS207 Combination Therapy in Triple-negative Breast Cancer
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07045311
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changchun, Dalian, Hangzhou, Harbin, Hefei, Nanjing, Qingdao, Shenyang, Shijiazhuang, Urumqi, Wuhan, Xi'an, Zhengzhou
- RecruitingA Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
- Phase
- Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT07060807
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Nanning, Taizhou, Urumqi, Xi'an, Xiamen, Xiangyang, Zhengzhou
- RecruitingA Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Phase
- Phase 3
- Started
- 2025-08
- Posted
- Registry
- NCT07062965
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 23 listed hospitals as study sitesBeijing, Changchun, Changsha, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Wenzhou, Wuhan, Xi'an
- RecruitingDragon Boat Race Versus Family Unsupervised Training to Improve the Physical Function and Quality of Life in Breast Cancer Patients
- Phase
- Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT07162298
Age 18 years to 75 years; women only (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingAn Investigational Study of BG-75202 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2025-12
- Posted
- Registry
- NCT07222267
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Changsha, Chongqing, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Xiamen
- RecruitingA Study on Predicting the Risk of Distant Metastasis in Breast Cancer Using AI-Generated Spatial Pathological Maps
- Phase
- Not given
- Started
- 2025-11
- Posted
- Registry
- NCT07244094
Age 18 years to 95 years; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang University; 1 listed hospital as study siteChangchun, Hangzhou
- RecruitingA Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors
- Phase
- Phase 1
- Started
- 2025-10
- Posted
- Registry
- NCT07250386
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingClinical Translation Research on a Multi-omics Breast Cancer Distant Metastasis Prediction Model Empowered by Artificial Intelligence
- Phase
- Not given
- Started
- 2025-12
- Posted
- Registry
- NCT07252986
Age not stated; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingSafety and Feasibility of IRE for Early-stage Breast Cancer: a Prospective, Open-Label, Single-Arm, Exploratory Study
- Phase
- N/A
- Started
- 2025-12
- Posted
- Registry
- NCT07263451
Age 18 years to Not stated; women only (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingPhase II Trial of Albumin-Bound Paclitaxel Combined With Nedaplatin (TP) Via Hepatic Arterial Infusion for Advanced Breast Cancer Patients With Liver Metastases After Failure of Standard Therapy
- Phase
- Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT07284836
Age 18 years to 70 years; women only (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingA Prospective Multicenter Study of the TuFEst-LN Model for Axillary Lymph Node Status Assessment in Breast Cancer
- Phase
- Not given
- Started
- 2025-08
- Posted
- Registry
- NCT07304934
Age 18 years to Not stated; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy
- Phase
- Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07330544
Age 18 years to Not stated; women only (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingNeoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer
- Phase
- Phase 2
- Started
- 2025-12
- Posted
- Registry
- NCT07340398
Age 18 years to 75 years; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingNeoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07351487
Age 18 years to 75 years; women only (registered criteria)
Led by First Affiliated Hospital, Zhejiang University; 2 listed hospitals as study sitesHangzhou, Hefei, Shanghai
- RecruitingA Study on the Efficacy and Safety of Switching Between Two Targeted Strategies, HP+Chemotherapy and HPy+Chemotherapy, After Treatment Progression in HER-2 Positive Advanced or Metastatic Breast Cancer
- Phase
- Not given
- Started
- 2025-03
- Posted
- Registry
- NCT07455188
Age 18 years to Not stated; women only (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingLevel I-II Axillary Irradiation in Breast Cancer With Sentinel-Node Macro-metastases
- Phase
- N/A
- Started
- 2025-10
- Posted
- Registry
- NCT07469267
Age 18 years to Not stated; women only (registered criteria)
Led by Fudan University Shanghai Cancer Center; 12 listed hospitals as study sitesChangsha, Guiyang, Hangzhou, Harbin, Jinan, Ningbo, Shanghai, Shijiazhuang, Tianjin, Wuhan
- RecruitingA Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2025-01
- Posted
- Registry
- NCT07673029
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 51 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Linyi, Luoyang, Meizhou, Nanchang, Nanning, Qingdao, Quanzhou, Shanghai, Shantou, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Weifang, Wuhan, Xi'an, Xinxiang, Xuzhou, Yantai, Zhengzhou
- RecruitingPucotenlimab and Anlotinib in Combination With Chemotherapy
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07896668
Age 18 years to Not stated (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingTargeted Resection of Axillary Metastatic Lymph Nodes After Breast Cancer Neoadjuvant Chemotherapy
- Phase
- N/A
- Started
- 2024-11
- Posted
- Registry
- NCT04744506
Age 18 years to 85 years; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
- Phase
- Not given
- Started
- 2024-01
- Posted
- Registry
- NCT06210776
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 41 listed hospitals as study sitesBeijing, Chengdu, Foshan, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Kunming, Luoyang, Nanchang, Nanjing, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Taiyuan, Tangshan, Tianjin, Urumqi, Weifang, Xi'an, Xinxiang, Xuzhou, Yinchuan, Zhengzhou, Zhuhai
- RecruitingThe Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity
- Phase
- Phase 3
- Started
- 2024-01
- Posted
- Registry
- NCT06214195
Age 18 years to Not stated (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingBeamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Phase
- Phase 1/Phase 2
- Started
- 2024-06
- Posted
- Registry
- NCT06324357
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesChangchun, Hangzhou, Harbin, Nanjing, Shanghai, Tianjin, Zhengzhou
- RecruitingA Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.
- Phase
- N/A
- Started
- 2024-10
- Posted
- Registry
- NCT06371274
Age 18 years to Not stated; women only (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingThe Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06452706
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesHangzhou, Harbin, Shanghai, Urumqi, Wuhan, Xi'an
- RecruitingRandomized Phase II Trial: Chest Wall RT Omission After Prosthetic Reconstruction
- Phase
- Phase 2
- Started
- 2024-09
- Posted
- Registry
- NCT06464913
Age 18 years to 70 years; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingMilaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
- Phase
- Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06534762
Age 18 years to 65 years (registered criteria)
Led by Zhejiang Provincial People's HospitalHangzhou
- RecruitingTislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis,an Exploratory, Single-Arm, Multicenter Phase II Clinical Study
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06538896
Age 18 years to 70 years; women only (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingRibociclib in Combination With Adjuvant Endocrine Therapy for Patients With Early High-risk HR+HER2- Breast Cancer
- Phase
- Not given
- Started
- 2024-01
- Posted
- Registry
- NCT06587789
Age 18 years to 80 years; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingAssessing Combined SBRT in Breast Cancer Non-Responders to Neoadjuvant Chemotherapy
- Phase
- Phase 1/Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06596018
Age 18 years to 75 years; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingNeoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)
- Phase
- Phase 2
- Started
- 2024-06
- Posted
- Registry
- NCT06611813
Age 18 years to 75 years; women only (registered criteria)
Led by First Affiliated Hospital, Zhejiang University; 6 listed hospitals as study sitesHangzhou, Harbin, Hefei, Shanghai, Urumqi, Zhengzhou
- RecruitingDrug Sensitivity of Hydrothorax and Ascite Organoids from Breast Cancer
- Phase
- Not given
- Started
- 2024-11
- Posted
- Registry
- NCT06658080
Age 18 years to 70 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang University; 1 listed hospital as study siteHangzhou
- RecruitingNeoadjuvant Toripalimab and Radiotherapy Treatment in N+ HR+ Breast Cancer
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06671262
Age 18 years to 85 years; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingNeoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)
- Phase
- Phase 2
- Started
- 2024-10
- Posted
- Registry
- NCT06682195
Age 18 years to 70 years; women only (registered criteria)
Led by First Affiliated Hospital, Zhejiang University; 10 listed hospitals as study sitesHangzhou, Harbin, Hefei, Nanchang, Shanghai, Taiyuan, Urumqi, Xi'an, Zhengzhou
- RecruitingRadiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.
- Phase
- Phase 2
- Started
- 2024-07
- Posted
- Registry
- NCT06705127
Age 18 years to 75 years (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingNeoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06832904
Age 18 years to 75 years; women only (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingMecapegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Advanced Breast Cancer
- Phase
- Not given
- Started
- 2024-10
- Posted
- Registry
- NCT07899099
Age 18 years to Not stated (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingProphylactic Irradiation to the Contralateral Breast for BCAs Patients
- Phase
- N/A
- Started
- 2023-01
- Posted
- Registry
- NCT04960839
Age 30 years to 70 years; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang University; 5 listed hospitals as study sitesHangzhou, Nanchang, Shanghai
- RecruitingEfficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks
- Phase
- Phase 3
- Started
- 2023-03
- Posted
- Registry
- NCT05212454
Age 18 years to 70 years; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
- Phase
- Phase 3
- Started
- 2023-06
- Posted
- Registry
- NCT05646862
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChangchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Tianjin, Wuhan
- RecruitingEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Phase
- Phase 3
- Started
- 2023-10
- Posted
- Registry
- NCT05696626
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 57 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Haikou, Hangzhou, Kunming, Lanzhou, Linyi, Luoyang, Luzhou, Meizhou, Nanchang, Nanjing, Nanning, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xiangyang, Xuzhou, Zhengzhou
- RecruitingSafety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2023-09
- Posted
- Registry
- NCT05860465
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Kunming, Luoyang, Nanjing, Shenyang, Shijiazhuang, Tianjin, Xi'an, Yinchuan
- RecruitingEfficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.
- Phase
- Phase 2
- Started
- 2023-09
- Posted
- Registry
- NCT05872347
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesAnyang, Beijing, Bengbu, Changchun, Guangzhou, Hangzhou, Harbin, Hefei, Luoyang, Nanjing, Nanning, Shijiazhuang, Tianjin, Urumqi, Wuhan, Xiangyang, Yinchuan, Zhengzhou
- RecruitingA Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2023-09
- Posted
- Registry
- NCT05894239
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Chengdu, Fuzhou, Hangzhou, Jinan, Luoyang, Nanchang, Nanning, Shijiazhuang, Tianjin, Wuhan
- RecruitingTrastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT05950945
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesBeijing, Fuzhou, Hangzhou, Hefei, Jinan, Kunming, Nanchang, Qingdao, Shanghai, Xi'an, Zhengzhou
- RecruitingA Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
- Phase
- Phase 1
- Started
- 2023-08
- Posted
- Registry
- NCT06043466
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou
- RecruitingA Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
- Phase
- Phase 1/Phase 2
- Started
- 2023-09
- Posted
- Registry
- NCT06064812
Age 18 years to Not stated; women only (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesChangchun, Chengdu, Guangzhou, Hangzhou, Hefei, Jinan, Luoyang, Nanjing, Nanning, Shanghai, Shenyang, Tianjin, Wuhan, Zhengzhou
- RecruitingJSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06079983
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 60 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Hengyang, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Meizhou, Nanchang, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xiangyang, Xining, Xinxiang, Xuzhou, Zhanjiang, Zhengzhou, Zunyi
- RecruitingA Study of YL202 in Selected Patients With Advanced Solid Tumors
- Phase
- Phase 2
- Started
- 2023-12
- Posted
- Registry
- NCT06107686
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jinan, Meizhou, Nanchang, Nanning, Qingdao, Shanghai, Shantou, Shenyang, Suzhou, Taiyuan, Taizhou, Urumqi, Weifang, Wuhan, Xi'an, Xiangyang, Xuzhou, Zhengzhou
- RecruitingOrganoids Based Drug Sensitivity in Neoadjuvant Chemotherapy of Breast Cancer
- Phase
- Not given
- Started
- 2023-12
- Posted
- Registry
- NCT06155305
Age 18 years to 70 years; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingNeoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer
- Phase
- Phase 2
- Started
- 2023-07
- Posted
- Registry
- NCT06227117
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChangsha, Hangzhou, Shanghai, Tianjin
- RecruitingPyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast Cancer
- Phase
- Phase 2
- Started
- 2023-02
- Posted
- Registry
- NCT07014410
Age 18 years to 75 years; women only (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingComparison of the Safety and Aesthetic Outcomes of a Novel Endoscopic-Assisted Breast-Conserving Surgery (SRRSHzb-EABCS) With Those of Conventional Breast-Conserving Surgery
- Phase
- N/A
- Started
- 2023-07
- Posted
- Registry
- NCT07920094
Age 18 years to 70 years; women only (registered criteria)
Led by Sir Run Run Shaw Hospital; 10 listed hospitals as study sitesHangzhou, Jinhua, Ningbo, Taizhou, Wenzhou
- RecruitingA Study for the Neoadjuvant Treatment of Breast Cancer
- Phase
- Phase 4
- Started
- 2022-07
- Posted
- Registry
- NCT05420454
Age 18 years to Not stated; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Study for the Adjuvant Treatment of Breast Cancer
- Phase
- Phase 4
- Started
- 2022-07
- Posted
- Registry
- NCT05420467
Age 18 years to Not stated; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingRinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Phase
- Phase 1/Phase 2
- Started
- 2022-12
- Posted
- Registry
- NCT05579366
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan
- RecruitingObservational of Adjuvant Treatment of Breast Cancer With Liposomal Doxorubicin Regimen
- Phase
- Not given
- Started
- 2022-05
- Posted
- Registry
- NCT05731258
Age 18 years to 75 years; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingA Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer
- Phase
- Phase 3
- Started
- 2022-01
- Posted
- Registry
- NCT05851014
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesBengbu, Changchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Linyi, Nanchang, Nanjing, Nanning, Ningbo, Shanghai, Shenyang, Wenzhou, Wuhan, Xi'an, Yinchuan, Zhengzhou
- RecruitingEfficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in ABC
- Phase
- Not given
- Started
- 2022-03
- Posted
- Registry
- NCT05856383
Age 18 years to Not stated (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- RecruitingEfficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer With Different HER2 Expression Patterns
- Phase
- Not given
- Started
- 2022-10
- Posted
- Registry
- NCT06551220
Age 18 years to 80 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Foshan, Fuzhou, Guangzhou, Hangzhou, Hengyang, Nanjing, Shanghai, Shantou, Shenzhen, Zhuhai
- RecruitingRadical Local vs. Palliative Therapy for Breast Cancer Patientts With Ipsilateral Humerus or Sternum Oligometastasis
- Phase
- N/A
- Started
- 2020-05
- Posted
- Registry
- NCT04158843
Age 18 years to 75 years; women only (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou
- RecruitingStudy to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
- Phase
- Phase 2
- Started
- 2020-09
- Posted
- Registry
- NCT04557449
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Wuhan, Xi'an, Zhengzhou
- RecruitingEfficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer
- Phase
- Phase 2/Phase 3
- Started
- 2020-09
- Posted
- Registry
- NCT04576143
Age 18 years to 70 years; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- RecruitingApplication of Radiomics in Breast Cancer
- Phase
- Not given
- Started
- 2018-01
- Posted
- Registry
- NCT04483804
Age 18 years to 80 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingAreola Preservation in NSM With Nipple Involvement
- Phase
- N/A
- Started
- 2026-05
- Posted
- Registry
- NCT07544134
Age 18 years to Not stated; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingResearch on AI Models for Predicting Breast Cancer Treatment Effectiveness to Guide Her-2 Targeted ADC Therapy
- Phase
- Not given
- Started
- 2026-08
- Posted
- Registry
- NCT07689929
Age not stated; women only (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- Not yet recruitingCulmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07745257
Age 18 years to 80 years; women only (registered criteria)
Led by Sun Yat-sen University Cancer Center; 8 listed hospitals as study sitesAnyang, Chengdu, Dalian, Guangzhou, Hangzhou, Nanchang, Nanjing, Shijiazhuang, Zhengzhou
- Not yet recruitingSHR-A1811 Monotherapy or Sequential THPy as Neoadjuvant Therapy for Stage II-III HER2-Positive Breast Cancer
- Phase
- Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07787338
Age 18 years to 75 years; women only (registered criteria)
Led by First Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingChinese Herbal Acupoint Application Combined With Triple Antiemetic Therapy for Prevention of Chemotherapy-Induced Nausea and Vomiting in Breast Cancer
- Phase
- Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07848984
Age 18 years to Not stated (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingAdding Preoperative Radiotherapy Based on Early Treatment Response in Breast Cancer
- Phase
- Phase 2
- Started
- 2026-11
- Posted
- Registry
- NCT07892508
Age 18 years to 75 years (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingCorrelation Between COVID-19 and Radiation Pneumonitis in Breast Cancer
- Phase
- Not given
- Started
- 2025-09
- Posted
- Registry
- NCT07188116
Age 18 years to 80 years; women only (registered criteria)
Led by Zhejiang Hospital; 1 listed hospital as study siteHangzhou
- Not yet recruitingComparing the Safety and Cosmetic Outcomes Between Laparoscopic Versus Traditional Open Breast-conserving Surgery
- Phase
- N/A
- Started
- 2024-10
- Posted
- Registry
- NCT06671249
Age 18 years to Not stated; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingEfficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer
- Phase
- Phase 4
- Started
- 2023-07
- Posted
- Registry
- NCT05841849
Age 18 years to 70 years; women only (registered criteria)
Led by Second Affiliated Hospital, Zhejiang UniversityHangzhou
- Not yet recruitingClinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis
- Phase
- Phase 4
- Started
- 2023-10
- Posted
- Registry
- NCT05860907
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer Center; 6 listed hospitals as study sitesChangsha, Hangzhou, Shanghai, Shijiazhuang, Yangzhou, Zhengzhou
- Not yet recruitingThe Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.
- Phase
- Phase 1/Phase 2
- Started
- 2023-11
- Posted
- Registry
- NCT06140576
Age 18 years to 70 years; women only (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
- Enrolling by invitationA Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07376629
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 22 listed hospitals as study sitesAnyang, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanjing, Shanghai, Shenyang, Suzhou, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou
- Enrolling by invitationT-DM1 Combined With CDK4/6 Inhibitor Ribociclib
- Phase
- Phase 2
- Started
- 2023-10
- Posted
- Registry
- NCT06481956
Age 18 years to 75 years (registered criteria)
Led by Zhejiang Cancer HospitalHangzhou
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Disease research in Hangzhou
Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.
A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.
| Cancer | Blood disorders | Other diseases | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital | Nasopharyngeal carcinoma | Oesophageal squamous cell carcinoma | Hepatocellular carcinoma | Stomach cancer | Lung cancer | Pancreatic cancer | Breast cancer | Glioma | Hepatoblastoma | Retinoblastoma | Chordoma | Osteosarcoma | Gastrointestinal stromal tumour | Neuroblastoma | Ewing sarcoma | Multiple myeloma | B-cell acute lymphoblastic leukaemia | Aplastic anaemia | Haemophagocytic lymphohistiocytosis | Lymphoma | Beta thalassaemia | Haemophilia A | Atypical haemolytic uraemic syndrome | Thrombotic thrombocytopenic purpura | Fanconi anaemia | Neuromyelitis optica spectrum disorder | IgG4-related disease | Myasthenia gravis | Moyamoya disease | Wilson disease | Biliary atresia | Coronary heart disease | Congenital heart disease | Scoliosis | Anti-NMDA receptor encephalitis | Takayasu arteritis | Hepatic echinococcosis | Idiopathic pulmonary fibrosis | Lymphangioleiomyomatosis | Amyotrophic lateral sclerosis | Spinal muscular atrophy | Fabry disease | Pompe disease | Duchenne muscular dystrophy | Behçet disease | Alport syndrome | IgA nephropathy | Gaucher disease | Niemann–Pick disease type C | Osteogenesis imperfecta | Primary biliary cholangitis | Primary sclerosing cholangitis | Congenital diaphragmatic hernia | Hirschsprung disease | Inherited epidermolysis bullosa | Hereditary angioedema | Familial adenomatous polyposis | Leber hereditary optic neuropathy | Majeed syndrome | NGLY1 deficiency | ISG15 deficiency | Shortlist |
| Affiliated Hospital of Hangzhou Normal University杭州师范大学附属医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | 4 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | |
| Children's Hospital, Zhejiang University School of Medicine浙江大学医学院附属儿童医院 | none | none | none | none | none | none | none | 81 open | 1 | none | none | 5 | none | 7 | none | none | 5 | 2 | 8 | 41 open | none | 0 | none | 1 | none | none | none | 11 open | none | none | 2 | 3 | 313 open | 4 | none | none | none | none | none | 1 | 2 | 21 open | none | 0 | none | 0 | 74 open | none | 0 | none | none | none | 0 | 4 | none | none | none | 4 | 1 | none | none | |
| Chun'an First People's Hospital淳安县第一人民医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Affiliated Hospital of Zhejiang Chinese Medical University浙江中医药大学附属第一医院(浙江省中医院) | none | none | none | 29 | 50 | none | 49 | none | none | none | none | 2 | 1 | none | none | 2 | none | 241 open | none | 8 | none | 24 | none | 1 | none | none | none | 4 | none | none | none | 2 | none | 33 open | 1 | none | none | 1 | none | 1 | none | 1 | none | none | 2 | none | 2 | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | |
| First Affiliated Hospital, Chinese Medical University浙江中医药大学附属第一医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Affiliated Hospital, Zhejiang University浙江大学医学院附属第一医院 | 5 | 11 | 2588 open | 6514 open | 1272 open | 11514 open | 6412 open | 32 | none | 1 | none | 8 | 91 open | 51 open | 0 | 556 open | 513 open | 11 open | 14 | 6711 open | none | 4 | 1 | 1 | none | 3 | 2 | 01 open | none | 41 open | 2 | 21 | 17 | none | 4 | 1 | 0 | 4 | none | 5 | none | 2 | none | 0 | 2 | 0 | 2 | 01 open | 1 | 1 | 4 | 4 | none | 1 | none | none | 0 | none | none | none | none | |
| Fourth Affiliated Hospital of Zhejiang University浙江大学医学院附属第四医院 | none | none | 6 | none | 93 open | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | 4 | none | none | none | |
| Fourth Affiliated Hospital, Zhejiang University | none | none | none | none | none | 6 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hangzhou Cancer Hospital杭州市肿瘤医院 | 1 | 4 | none | none | 131 open | 11 open | none | none | none | 1 | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hangzhou Children's Hospital杭州市儿童医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hangzhou First People's Hospital杭州市第一人民医院 | 8 | none | 67 | 11 | 51 | 231 open | 21 | 8 | none | 1 | none | 3 | 1 | none | none | 5 | none | none | none | 7 | none | none | none | none | none | none | none | none | none | none | none | 16 | 1 | none | none | none | none | 1 | none | 2 | none | 1 | none | 1 | 1 | none | 0 | none | none | none | 1 | none | none | none | none | none | none | 0 | none | none | none | |
| Hangzhou Fuyang District First People's Hospital杭州市富阳区第一人民医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hangzhou Hospital, Zhejiang Chinese Medicine University | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hangzhou Lin'an Traditional Chinese Medicine Hospital杭州市临安区中医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hangzhou Linping District First People's Hospital杭州市临平区第一人民医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hangzhou Red Cross Hospital杭州市红十字会医院 | none | none | none | none | none | none | none | none | none | none | none | none | 1 | 1 | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hangzhou TCM Hospital, Zhejiang Chinese Medical University杭州市中医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | 14 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hangzhou Third People's Hospital杭州市第三人民医院 | none | none | none | none | none | none | none | none | none | none | none | 3 | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hangzhou Women's Hospital杭州市妇科医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 3 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Hangzhou Xixi Hospital杭州市西溪医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 5 | 1 | none | none | none | none | none | none | none | none | none | |
| Jianggan District People's Hospital杭州市江干区人民医院 | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Second Affiliated Hospital of Zhejiang Chinese Medical University浙江中医药大学附属第二医院(浙江省新华医院) | none | none | none | none | none | none | none | none | none | none | none | 1 | 3 | none | 1 | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | 1 | none | none | none | none | none | none | none | none | none | |
| Second Affiliated Hospital, Zhejiang University浙江大学医学院附属第二医院 | 1 | 43 open | 689 open | 596 open | 11512 open | 665 open | 10931 open | 419 open | none | 1 | 0 | 16 | 5 | 3 | 0 | 52 open | none | none | 2 | 4320 open | none | none | none | 1 | none | 7 | none | 4 | 12 | 82 open | none | 368 open | 9 | 5 | 4 | 0 | none | 4 | none | 6 | none | 0 | 0 | 1 | 0 | 1 | 2 | none | none | 0 | none | none | 1 | 1 | none | 1 | 4 | 0 | none | none | none | |
| Shaoxing People's Hospital绍兴市人民医院 | none | none | none | 14 | 29 | 7 | none | 9 | none | none | none | 2 | none | 1 | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 3 | none | none | none | none | none | none | 1 | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shulan Hangzhou Hospital树兰(杭州)医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | |
| Sir Run Run Shaw Hospital浙江大学医学院附属邵逸夫医院 | 4 | 1 | 833 open | 44 | 831 open | 29 | 491 open | 15 | none | none | none | 10 | 2 | none | none | 4 | none | none | none | 7 | none | none | none | 1 | none | none | 3 | 0 | none | none | none | 232 open | 11 | none | none | 1 | none | 0 | 1 | 0 | none | none | 0 | none | 1 | none | 3 | none | 0 | none | 1 | 0 | none | none | none | none | none | none | none | none | none | |
| Third Affiliated Hospital of Zhejiang Chinese Medical University浙江中医药大学附属第三医院(浙江省中山医院) | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 4 | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Tongde Hospital浙江省立同德医院 | 0 | none | none | 20 | none | none | none | none | none | none | none | 0 | 8 | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Women's Hospital浙江大学医学院附属妇产科医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 6 | none | none | none | none | none | none | 0 | none | none | none | 0 | none | none | none | none | none | none | none | none | 1 | none | none | none | none | 1 | none | none | none | |
| Xiaoshan Traditional Chinese Medical Hospital杭州市萧山区中医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Zhejiang Cancer Hospital浙江省肿瘤医院 | 196 open | 506 open | 353 open | 10611 open | 2047 open | 232 open | 11015 open | 18 | 0 | none | none | 2 | 0 | 0 | none | 2 | none | 2 | 2 | 137 open | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | 1 | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | |
| Zhejiang Hospital浙江医院 | none | none | none | none | 31 | none | 6 | none | none | none | none | 0 | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 9 | 0 | none | 1 | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Zhejiang Hospital浙江医院 | none | none | none | none | none | none | 01 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 02 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Zhejiang Provincial People's Hospital浙江省人民医院 | 4 | 4 | 119 | 38 | 691 open | 533 open | 741 open | 241 open | none | 0 | none | 4 | 0 | 1 | 0 | 10 | none | none | none | 151 open | none | none | none | none | none | none | none | 2 | none | none | none | 12 | 5 | 3 | none | none | none | 1 | none | 1 | none | 1 | none | 0 | 0 | none | 4 | none | none | none | 4 | 2 | none | none | none | none | none | none | none | none | none | |
Column labels are short names. Choose one to open that disease in Hangzhou.
- Glioma 81 open
- Hepatoblastoma 1
- Osteosarcoma 5
- Neuroblastoma 7
- B-cell acute lymphoblastic leukaemia 5
- Aplastic anaemia 2
- Haemophagocytic lymphohistiocytosis 8
- Lymphoma 41 open
- Haemophilia A 0
- Thrombotic thrombocytopenic purpura 1
- Myasthenia gravis 11 open
- Biliary atresia 2
- Coronary heart disease 3
- Congenital heart disease 313 open
- Scoliosis 4
- Amyotrophic lateral sclerosis 1
- Spinal muscular atrophy 2
- Fabry disease 21 open
- Duchenne muscular dystrophy 0
- Alport syndrome 0
- IgA nephropathy 74 open
- Niemann–Pick disease type C 0
- Congenital diaphragmatic hernia 0
- Hirschsprung disease 4
- Leber hereditary optic neuropathy 4
- Majeed syndrome 1
- Stomach cancer 29
- Lung cancer 50
- Breast cancer 49
- Osteosarcoma 2
- Gastrointestinal stromal tumour 1
- Multiple myeloma 2
- Aplastic anaemia 241 open
- Lymphoma 8
- Haemophilia A 24
- Thrombotic thrombocytopenic purpura 1
- Myasthenia gravis 4
- Coronary heart disease 2
- Scoliosis 33 open
- Anti-NMDA receptor encephalitis 1
- Idiopathic pulmonary fibrosis 1
- Amyotrophic lateral sclerosis 1
- Fabry disease 1
- Behçet disease 2
- IgA nephropathy 2
- Primary biliary cholangitis 0
- Nasopharyngeal carcinoma 5
- Oesophageal squamous cell carcinoma 11
- Hepatocellular carcinoma 2588 open
- Stomach cancer 6514 open
- Lung cancer 1272 open
- Pancreatic cancer 11514 open
- Breast cancer 6412 open
- Glioma 32
- Retinoblastoma 1
- Osteosarcoma 8
- Gastrointestinal stromal tumour 91 open
- Neuroblastoma 51 open
- Ewing sarcoma 0
- Multiple myeloma 556 open
- B-cell acute lymphoblastic leukaemia 513 open
- Aplastic anaemia 11 open
- Haemophagocytic lymphohistiocytosis 14
- Lymphoma 6711 open
- Haemophilia A 4
- Atypical haemolytic uraemic syndrome 1
- Thrombotic thrombocytopenic purpura 1
- Neuromyelitis optica spectrum disorder 3
- IgG4-related disease 2
- Myasthenia gravis 01 open
- Wilson disease 41 open
- Biliary atresia 2
- Coronary heart disease 21
- Congenital heart disease 17
- Anti-NMDA receptor encephalitis 4
- Takayasu arteritis 1
- Hepatic echinococcosis 0
- Idiopathic pulmonary fibrosis 4
- Amyotrophic lateral sclerosis 5
- Fabry disease 2
- Duchenne muscular dystrophy 0
- Behçet disease 2
- Alport syndrome 0
- IgA nephropathy 2
- Gaucher disease 01 open
- Niemann–Pick disease type C 1
- Osteogenesis imperfecta 1
- Primary biliary cholangitis 4
- Primary sclerosing cholangitis 4
- Hirschsprung disease 1
- Familial adenomatous polyposis 0
- Nasopharyngeal carcinoma 8
- Hepatocellular carcinoma 67
- Stomach cancer 11
- Lung cancer 51
- Pancreatic cancer 231 open
- Breast cancer 21
- Glioma 8
- Retinoblastoma 1
- Osteosarcoma 3
- Gastrointestinal stromal tumour 1
- Multiple myeloma 5
- Lymphoma 7
- Coronary heart disease 16
- Congenital heart disease 1
- Idiopathic pulmonary fibrosis 1
- Amyotrophic lateral sclerosis 2
- Fabry disease 1
- Duchenne muscular dystrophy 1
- Behçet disease 1
- IgA nephropathy 0
- Primary biliary cholangitis 1
- Leber hereditary optic neuropathy 0
- Nasopharyngeal carcinoma 1
- Oesophageal squamous cell carcinoma 43 open
- Hepatocellular carcinoma 689 open
- Stomach cancer 596 open
- Lung cancer 11512 open
- Pancreatic cancer 665 open
- Breast cancer 10931 open
- Glioma 419 open
- Retinoblastoma 1
- Chordoma 0
- Osteosarcoma 16
- Gastrointestinal stromal tumour 5
- Neuroblastoma 3
- Ewing sarcoma 0
- Multiple myeloma 52 open
- Haemophagocytic lymphohistiocytosis 2
- Lymphoma 4320 open
- Thrombotic thrombocytopenic purpura 1
- Neuromyelitis optica spectrum disorder 7
- Myasthenia gravis 4
- Moyamoya disease 12
- Wilson disease 82 open
- Coronary heart disease 368 open
- Congenital heart disease 9
- Scoliosis 5
- Anti-NMDA receptor encephalitis 4
- Takayasu arteritis 0
- Idiopathic pulmonary fibrosis 4
- Amyotrophic lateral sclerosis 6
- Fabry disease 0
- Pompe disease 0
- Duchenne muscular dystrophy 1
- Behçet disease 0
- Alport syndrome 1
- IgA nephropathy 2
- Osteogenesis imperfecta 0
- Congenital diaphragmatic hernia 1
- Hirschsprung disease 1
- Hereditary angioedema 1
- Familial adenomatous polyposis 4
- Leber hereditary optic neuropathy 0
- Nasopharyngeal carcinoma 4
- Oesophageal squamous cell carcinoma 1
- Hepatocellular carcinoma 833 open
- Stomach cancer 44
- Lung cancer 831 open
- Pancreatic cancer 29
- Breast cancer 491 open
- Glioma 15
- Osteosarcoma 10
- Gastrointestinal stromal tumour 2
- Multiple myeloma 4
- Lymphoma 7
- Thrombotic thrombocytopenic purpura 1
- IgG4-related disease 3
- Myasthenia gravis 0
- Coronary heart disease 232 open
- Congenital heart disease 11
- Takayasu arteritis 1
- Idiopathic pulmonary fibrosis 0
- Lymphangioleiomyomatosis 1
- Amyotrophic lateral sclerosis 0
- Pompe disease 0
- Behçet disease 1
- IgA nephropathy 3
- Niemann–Pick disease type C 0
- Primary biliary cholangitis 1
- Primary sclerosing cholangitis 0
- Nasopharyngeal carcinoma 196 open
- Oesophageal squamous cell carcinoma 506 open
- Hepatocellular carcinoma 353 open
- Stomach cancer 10611 open
- Lung cancer 2047 open
- Pancreatic cancer 232 open
- Breast cancer 11015 open
- Glioma 18
- Hepatoblastoma 0
- Osteosarcoma 2
- Gastrointestinal stromal tumour 0
- Neuroblastoma 0
- Multiple myeloma 2
- Aplastic anaemia 2
- Haemophagocytic lymphohistiocytosis 2
- Lymphoma 137 open
- Fanconi anaemia 2
- Idiopathic pulmonary fibrosis 1
- Amyotrophic lateral sclerosis 1
- Duchenne muscular dystrophy 1
- Familial adenomatous polyposis 1
- Nasopharyngeal carcinoma 4
- Oesophageal squamous cell carcinoma 4
- Hepatocellular carcinoma 119
- Stomach cancer 38
- Lung cancer 691 open
- Pancreatic cancer 533 open
- Breast cancer 741 open
- Glioma 241 open
- Retinoblastoma 0
- Osteosarcoma 4
- Gastrointestinal stromal tumour 0
- Neuroblastoma 1
- Ewing sarcoma 0
- Multiple myeloma 10
- Lymphoma 151 open
- Myasthenia gravis 2
- Coronary heart disease 12
- Congenital heart disease 5
- Scoliosis 3
- Idiopathic pulmonary fibrosis 1
- Amyotrophic lateral sclerosis 1
- Fabry disease 1
- Duchenne muscular dystrophy 0
- Behçet disease 0
- IgA nephropathy 4
- Primary biliary cholangitis 4
- Primary sclerosing cholangitis 2
Other cities nearby
Straight-line distance from the city centre; counts are hospitals listed for breast cancer.
Counts are listed hospitals only, not every hospital in each city.
Where these numbers come from
Papers
English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions
Trials
ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Hangzhou on ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.